Healthcare News by GLG Council Members

Novartis, Sleeping Giant Wakes-Up in China

November 6, 2009

Analysis by:GLG Expert Contributor

Analysis of:Novartis to invest US$ 1 bn to build largest pharma R&D institute in China | www.pharmabiz.com

Novartis to grow its China presence, late.Novartis has a slow response to market opportunities.GlaxoSmithKline and other big pharma players are perhaps too large to compete in the world's changing markets.

Is GE Global Research Developing a Portable Solar-Powered Ultrasound Device?

November 6, 2009

Analysis by:GLG Expert Contributor

Analysis of:GE Global Research bags US$ 1.2 mn NIH project for developing technology in prenatal care | www.pharmabiz.com

As the recipient of a new NIH grant, GE Healthcare should create and design new innovative features as a way to differentiate its products in the nascent point-of-care portable ultrasound marketplace.  Reasons why GE Healthcare should pursue a risk-taking strategy, such as developing a portable solar-powered ultrasound device and background information supportive of this strategy is offered in the...

Robert Boorstein, MD, PhDAssociate Professor, PathologyNEW YORK UNIVERSITY (INC)

Potential impact of large clinical trial on Liquid based cytology market

November 5, 2009

Analysis of:Alternative to Pap Test Does Not Appear to Be Better for Detecting Cervical Cancer | www.medcompare.com

The data confirms what has long been known. There has never been definitive evidence for a benefit for Liquid based cytology screening compared with conventional screening, especially when sample collection is standardized and the laboratory meets reasonable standards.Objectively, liquid based cytology has essentially replaced conventional Pat testing in this country, and it is unlikely that there...

Ken PowellPresidentGenesis Business Development, LLC

FDA Publishes H1N1 Diagnostic Test Guidance

November 5, 2009

Analysis of:FDA Publishes Guidance Document for H1N1 Dx | www.genomeweb.com

The FDA published document designed to help diagnostic test manufactures develop H1N1 tests and data that would accompany a FDA application to market them.  This follows on the recent issuance of CDC guidelines for H1N1 tests.

Ken PowellPresidentGenesis Business Development, LLC

Genomic Health Posts a 41% Q3 Revenue Increase

November 5, 2009

Analysis of:Genomic Health Posts 41 Percent Revenue Increase for Q3 | www.genomeweb.com

Genomic Health (NASDAQ: GHDX) posted Q3 revenues that were 41% greater than Q3 08.  Virtually all of the revenue out performance was due to sales of the company's Oncotype Dx molecular diagnostic test for breast cancer used in developing a therapeutic strategy and assessing risk of recurrence.

Should we use 3D imaging for “routine orthodontic cases”?

November 4, 2009

Analysis by:GLG Expert Contributor

Analysis of:Should we use 3D imaging for “routine orthodontic cases”? | www.pcsortho.org

When 3D imaging became available for practitioners in Orthodontics, Oral Surgery and Dentistry, the question most often asked is: "Does 3D imaging really make any difference in my treatment planning and treatment of my patients?" The information gained with 3D imaging is obvious, but does it really make any difference, especially in 'routine cases'?

Ken PowellPresidentGenesis Business Development, LLC

Court Denies Lawsuit Dismissal Motion by Myriad Genetics and Others

November 4, 2009

Analysis of:Court Denies Motion to Dismiss BRCA Patent Suit Against Myriad, Others | www.genomeweb.com

The US District Court for the Southern District of New York denied a motion to dismiss the lawsuit brought against Myriad Genetics, the US Patent and Trademark Office and the University of Utah Research Foundation by the Association for Molecular Pathology, the American Civil Liberties Union and Public Patent Foundation at the Benjamin N. Cardozo School of Law, and others.  This outcome of this lawsuit...

What Will Help The Poor?

November 3, 2009

Analysis by:GLG Expert Contributor

Analysis of:Deficit Plays into Health Reform | www.washingtonpost.com

There is no doubt that a great deal of time, efforts and resources have gone into trying to find a solution to the healthcare problems and concerns that we deal with today. What is not as clear to those who really need these problems solved are the answers thus far. A lot of very smart people seem to have forgotten the actual value of a person. What ever numbers show up on the balance sheet hardly...

Eric Whitman, MDMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC

Synta Drug for Metastatic Melanoma Not Dead Yet (?)

November 3, 2009

Analysis of:Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRYSM Data Presented at Melanoma XIII | www.businesswire.com

Updated data presented at an annual Melanoma conference suggests the drug Elesclomol may benefit a subset of patients treated on a Phase III trial. This Synta Pharmaceuticals-sponsored trial in metastatic melanoma patients was stopped for safety (survival) concerns in February 2009, but the updated analysis suggests that a commonly available biomarker may identify patients who appear to benefit from...

Pharma Outsourcing: Where Will it End?

November 3, 2009

Analysis by:GLG Expert Contributor

Analysis of:Quintiles inks pharma deals | www.outsourcing-pharma.com

A major supplier of clinical development services has just been awarded all of Astra Zeneca's clinical pharmacology work. Such work was traditionally performed internally but is now one of many stages of development being outsourced. This follows similar trends in research, where pharma companies are forging external relationships. We question where the pharma industry is headed and how much of its...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 7647